Sisu vaatamiseks vahele jätta
Tagasi otsingule
See tellimus on aegunud.

Poola – Ravimid – ZP/91/2026 Sukcesywna dostawa produktu leczniczego na potrzeby badania klinicznego realizowanego w projekcie "B cell depletion therapy to improve outcomes of steroid-sensitive nephrotic syndrome in adults-BOOSTER Trial”

Uniwersytet Medyczny w ŁodziPoolaAvaldatud 11. okt 2026
Tähtaja möödunud

Kirjeldus

Zamowlenie on the subject is the successive delivery of a medicinal product for the needs of a clinical trial carried out in the project "B cell depletion therapy to improve outcomes of steroid-sensitive nephrotic syndrome in adults - BOOSTER Trial", financed from the funds of the Medical Research Agency within the competition ABM/2023/1. The delivery of medicinal products should be carried out in accordance with the principles of GCP, GMP and GDP. The subject of the order includes: 1. Purchase of the medicinal product Rytuksymab (trade name: RIXIMYO), Concentrate for the preparation of a solution for infusion, 10 mg/ml (500 mg), 1 vial. 50 ml, in the amount: 150 vials, with a validity period of not less than 14 months from the date of delivery of the product. The medicinal product containing the active substance Rytuksymab must be authorized for economic activity in the territory of the European Union. The characteristics of the medicinal product containing the active substance Rytuksymab should contain information on the possibility of using an alternative dosing regimen based on the administration of the second and subsequent infusions at a higher speed using a drug solution with the same concentration as in the previous infusions (4 mg/ml in a volume of 250 ml). The initial infusion rate should be 250 mg/hour for the first 30 minutes, and then 600 mg/hour for the next 90 minutes. 2. Transport of the medicinal product Rytuksymab to a maximum of 20 research centers indicated by the Contracting Authority in Poland. Drug deliveries will be made according to partial orders placed by the authorized representative of the Contracting Authority, based on the demand resulting from the recruitment and inclusion of patients in the clinical trial. Orders will be placed by telephone or to the e-mail address indicated by the Contractor. The maximum order fulfillment time is 5 working days. The final deadlines and quantities of products will be determined by the Contracting Authority with the selected Contractor during the execution of the contract. A maximum of 10 deliveries of the drug to the center is expected. In addition to partial orders, the need for urgent orders in a limited number (no more than 2 per year for a given research center) is allowed. Urgent orders will be reported to the Contractor by the authorized representative of the Contracting Authority to the telephone number and email address indicated by the Contractor. The maximum time for delivering the drug from placing an urgent order is 2 working days. 3. The Contractor is obliged to provide a list containing information about the contents of a given package and the assigned batch numbers. The Contractor should have a current permit for wholesale trade in medicinal products, i.e. be listed in the Register of Permits for Conducting Pharmaceutical Wholesale conducted by the Chief Pharmaceutical Inspector, in accordance with Article 83 of the Pharmaceutical Law and the Regulation of the Minister of Health of 3 October 2012, on the description of the teleinformatics system in which the Register of Permits for Conducting Pharmaceutical Wholesale is conducted. Implementation period: The order will be implemented within 29 months from the date of signing the contract but no later than 31.05.2029.

CPV koodid

Pharmaceutical productsVarious medicinal products

Dokumendid & esitamine

AI kokkuvõte
Logi sisse AI kokkuvõtte jaoks

Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.

Seotud hanked